Oncology Today with Dr Neil Love: Recent Episodes
Research To Practice
Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.
Dr Martin Hutchings from Rigshospitalet, Copenhagen University Hospital in Copenhagen, Denmark, and Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://researchtopractice.com/InsidetheIssue2023/NHL)
Prof Georgina Long from the University of Sydney in Sydney, New South Wales, Australia, discusses optimizing the management of melanoma moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/MTPMelanoma23)
Featuring a discussion on BTK inhibitors for the management of mantle cell lymphoma with Dr Michael Wang, moderated by Dr Neil Love. CME information and select publications here (https://researchtopractice.com/OncologyTodayBTKInhibitorsMCL23).
Dr Richard F Riedel from Duke Cancer Institute in Durham, North Carolina, discusses approved and novel treatment approaches for soft tissue sarcoma, moderated by Dr Neil Love. CME information and select publications here (http://www.ResearchToPractice.com/MTPSarcoma23/Part2).
Dr Jeremy Abramson from Massachusetts General Hospital in Boston discusses key presentations on chronic lymphocytic leukemia and lymphomas from recent oncology/hematology conferences. CME information and select publications here (https://researchtopractice.com/OncologyTodayPostConf23/CLLLymphoma)
Dr Rana McKay from UC San Diego Moores Cancer Center in La Jolla, California discusses key presentations on genitourinary cancers from the 2023 ASCO Annual Meeting. CME information and select publications here (https://researchtopractice.com/OncologyTodayPostASCO23/GU)
Dr Aditya Bardia from Massachusetts General Hospital in Boston, Massachusetts, and Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discuss approved and novel treatment approaches for ER-positive metastatic breast cancer that has progressed on prior CDK4/6 inhibitor therapy. CME information and select publications here (https://researchtopractice.com/InsideTheIssue2023/ERPositivemBC).
Dr Hans Lee from The University of Texas MD Anderson Cancer Center in Houston, Texas, and Dr Saad Zafar Usmani from Memorial Sloan Kettering Cancer Center in New York, New York, discuss approved and novel bispecific antibodies and their current and potential roles in the treatment of multiple myeloma. CME information and select publications here (https://www.researchtopractice.com/InsidetheIssue2023/MM).
Dr Matthew Gubens from the University of California in San Francisco, California, discusses key presentations on lung cancer from the 2023 ASCO Annual Meeting moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://ResearchToPractice.com/OncologyTodayPostASCO23/Lung)
Dr Kerry Rogers from the Ohio State University in Columbus, Ohio, discusses the education and care of patients with chronic lymphocytic leukemia. NCPD information and select publications here (https://www.researchtopractice.com/ONS2023CLLReview/InterviewAudio)
Featuring perspectives from Dr Omid Hamid and Dr Evan J Lipson moderated by Dr Neil Love. Produced by Research to Practice. CME information and select publications here (http://www.researchtopractice.com/YiR2022/SkinCancers).
Dr Philip Philip from Henry Ford Cancer - Detroit in Michigan discusses key presentations on GI cancers from the 2023 ASCO Annual Meeting moderated by Dr Neil Love. Produced by Research to Practice. CME information and select publications here (https://researchtopractice.com/OncologyTodayPostASCO23/GI)
Dr Floor Backes from The James Cancer Hospital and Solove Research Institute in Columbus, Ohio, discusses recent updates from ASCO 2023 on the management of gynecologic cancers. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayPostASCO23/Gyn)
Drs Neeraj Agarwal, Emmanuel Antonarakis, Karim Fizazi and Susan Slovin discuss the current and future role of PARP inhibitors in the management of prostate cancer. CME information and select publications here (https://www.researchtopractice.com/PARPProstateThinkTank2023).
Dr Terence Friedlander from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and Dr Petros Grivas from the Fred Hutchinson Cancer Research Center in Seattle, Washington, discuss available and novel treatment strategies for metastatic urothelial bladder cancer moderated by Dr Neil Love. CME informationa and select publications here (https://www.researchtopractice.com/InsideTheIssue2023/mUBC).
Dr Heather McArthur from the UT Southwestern Medical Center in Dallas, Texas discusses key presentations on breast cancer from the 2023 ASCO Annual meeting. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayPostASCO23/BreastCancer).
Dr David O’Malley from The James Cancer Center in Columbus, Ohio, discusses recent advances in the management of ovarian cancer, including presentations from ASCO 2023. CME information and select publications here (https://researchtopractice.com/ASCO2023Ovarian/AudioInterview)
Dr Tanios Bekaii-Saab from the Mayo Clinic in Phoenix, Arizona, discusses the role of novel therapeutic management approaches for patients with colorectal and gastroesophageal cancers. NCPD information and select publications here (https://www.researchtopractice.com/ONS2023GE/AudioInterview)
Featuring perspectives from Dr Guillermo Garcia-Manero and Dr David Sallman. CME information and select publications here (http://www.researchtopractice.com/InsidetheIssue2023/MDS)
Dr Hanny Al-Samkari from Harvard Medical School in Boston, Massachusetts, discusses the presentation and management of immune thrombocytopenia. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayITP23)
Dr Carlos de Castro from Duke Cancer Institute in Durham, North Carolina discusses the presentation, diagnosis and management of paroxysmal nocturnal hemoglobinuria. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayPNH23)
Dr Robin “Katie” Kelley from the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California discusses recent updates from ASCO 2023 on the management of hepatobiliary cancers, moderated by Dr Neil Love. CME information and select publications here (http://www.ResearchToPractice.com/ASCO2023HBC/AudioInterview)
Dr Matthew Galsky discusses recent updates from ASCO 2023 on the management of urothelial bladder cancer moderated by Dr Neil Love. Produced by Research to Practice. CME information and select publications here (http://www.ResearchToPractice.com/ASCO2023Bladder/AudioInterview)
Featuring a discussion on recent presentations in breast cancer from the 2023 ASCO annual meeting with Dr Kevin Kalinsky moderated by Dr Neil Love. Produced by Research to Practice. CME information and select publications [here (http://www.ResearchToPractice.com/ASCO2023Breast/AudioInterview)
Dr Elizabeth Plimack from Fox Chase Cancer Center in Philadelphia, Pennsylvania, discusses available and emerging therapies for patients with urothelial bladder cancer. CME information and select publications here (https://www.researchtopractice.com/ONS2023Bladder/Audiointerview)
Featuring perspectives from Dr Bradley J Monk and Dr Matthew A Powell moderated by Dr Neil Love. Produced by Research to Practice. CME information and select publications here (http://www.researchtopractice.com/PostSGO23Endometrial).
Dr Ian W Flinn discusses the management of Hodgkin and non-Hodgkin lymphoma. CME information and select publications here (http://www.researchtopractice.com/MTPLymphoma23/)
Dr Brian Van Tine discusses new and future research in the management of soft tissue sarcoma and related connective tissue disorders. CME information and select publications here (http://www.researchtopractice.com/MTPSarcoma23/Part1)
Dr Ruben Mesa from the Mays Cancer Center in San Antonio, Texas, discusses therapeutic advances in the management of patients with myelofibrosis. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNovelAgentsMF22).
Dr Toni Choueiri from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent therapeutic advances in the care of patients with renal cell carcinoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayRCC22).
Professor Arndt Vogel from Hannover Medical School in Germany discusses major clinical trials and recent changes in the treatment of advanced hepatocellular carcinoma. CME information and select publications [here] (http://www.researchtopractice.com/OncologyTodayHCC22)
Dr Eytan Stein from Memorial Sloan Kettering Cancer Center in New York City discusses novel agents and strategies in the treatment of acute myeloid leukemia. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNovelAgentsAML22).
Dr Amy DeZern from The Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, discusses recent therapeutic advances in higher-risk myelodysplastic syndromes. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHigherRiskMDS22).
Dr Rachna Shroff from the University of Arizona Cancer Center in Tucson, Arizona, discusses data and the practical implications from key gastrointestinal cancer presentations made at recent major oncology conferences. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayGI22).
Dr Rebecca Heist from Massachusetts General Hospital Cancer Center in Boston, Massachusetts discusses recent therapeutic advances in the management of MET-altered non-small cell lung cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMETAlteredNSCLC22).
Dr Brady Stein from Northwestern University Feinberg School of Medicine in Chicago, Illinois, discusses recent therapeutic advances in myelofibrosis. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMF22).
Dr Pamela Kunz from the Yale Cancer Center in Palo Alto, California, discusses recent therapeutic advances in neuroendocrine tumors. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNeuroendocrine22).
Professor Axel Hauschild from Kiel University in Kiel, Germany, discusses recent therapeutic advances in the treatment of metastatic melanoma with BRAF mutations. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayBRAFMelanoma22).
Dr Justin Gainor from Massachusetts General Hospital in Boston, Massachusetts, discusses recent therapeutic advances in non-small cell lung cancer with RET fusions. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayRETNSCLC22).
Professor Sia Daneshmand from the USC/Norris Comprehensive Cancer Center in Los Angeles, California, discusses recent advances in and perspectives on the management of nonmetastatic urothelial bladder cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNonmetastaticBladder22).
Dr Benjamin Levy from the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses recent therapeutic advances in the care of patients with small cell lung cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodaySCLC22).
Dr Amrita Krishnan from City of Hope in Duarte, California, discusses recent therapeutic advances in BCMA-directed therapies for multiple myeloma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayBCMAMM22).
Dr Heather Wakelee from Stanford Cancer Institute in Palo Alto, California, discusses the management of localized non-small cell lung cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayLocalizedNSCLC22).
Dr Stephen Ansell from the Mayo Clinic in Rochester, Minnesota, reviews the evolution of the Hodgkin lymphoma treatment landscape. CME information and select publications here (http://www.researchtopractice.com/OncologyToday22HL).
Dr Charles Powell from the Mount Sinai National Jewish Health Respiratory Institute in New York discusses the diagnosis and treatment of interstitial lung disease in patients receiving anticancer therapy. CME information and select publications here (http://www.researchtopractice.com/OncologyToday22ILD).
Dr Mansoor Raza Mirza from Copenhagen University Hospital in Copenhagen, Denmark, discusses recent therapeutic advances in the care of patients with endometrial cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyToday22Endometrial).
Dr Asim Farooq from The University of Chicago Medical Center in Chicago, Illinois, discusses common ocular toxicities associated with anticancer agents, including antibody-drug conjugates and EGFR, ALK, MEK and BRAF inhibitors. CME information and select publications here (http://www.researchtopractice.com/OncologyToday22OcularToxicities).
Dr Joshua Sabari from the Perlmutter Cancer Center in New York discusses key presentations in lung cancer from the 2022 ASCO annual meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASCOLung22).
Dr Alexander Spira of the Virginia Cancer Specialists Research Program in Fairfax, Virginia, discusses recent therapeutic advances in the care of patients with non-small cell lung cancer with KRAS mutations. CME information and select publications here (http://www.researchtopractice.com/OncologyToday22KRASMutantNSCLC).
Dr Brian Slomovitz from the Mount Sinai Medical Center in Miami, Florida, discusses key abstracts in gynecologic cancers presented at the 2022 ASCO annual meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASCOGyn22).
Dr Ezra Cohen from the Moores Cancer Center at UC San Diego Health in La Jolla, California, discusses key abstracts presented in head, neck and thyroid cancers at the 2022 ASCO annual meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASCOHN22).
Dr Shanu Modi from Memorial Sloan Kettering Cancer Center in New York discusses recent therapeutic advances in HER2-low breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHER2Low2/22).
Dr Jeffrey Bradley from the Emory University School of Medicine in Atlanta, Georgia, and Dr David Spigel from the Sarah Cannon Research Institute in Nashville, Tennessee, discuss the past, present and future management of unresectable Stage III non-small cell lung cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayStageIIINSCLC22).
Dr Sandy Srinivas from Stanford University in California discusses key abstracts across genitourinary cancers presented at the 2022 ASCO annual meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASCOGU22).
Professor Juan Valle from The Christie NHS Foundation Trust in Manchester, United Kingdom, discusses the evolving treatment landscape in biliary tract cancers. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCholangiocarcinoma22).
Dr Angela DeMichele from the University of Pennsylvania in Philadelphia discusses key abstracts in breast cancer presented at the 2022 ASCO annual meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASCOBreast22).
Dr Adam Brufsky from the UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania, discusses recent data in HER2-low breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyToday22HER2LowBC).
Dr Loretta Nastoupil from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses recent advances and future directions in the treatment of patients with follicular lymphoma. CME information and select publications here (http://www.researchtopractice.com/OncologyToday22FollicularLymphoma).
Dr David O’Malley from The Ohio State University and The James Cancer Center in Columbus, Ohio, discusses trials in ovarian cancer presented at SGO 2022. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostSGO22).
Dr Judy Garber from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent data with PARP inhibitors for breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPARPBreast22).
Dr Mark Agulnik from City of Hope in Duarte, California, discusses recent therapeutic advances in soft tissue sarcoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodaySoftTissue22).
Dr Ajai Chari from the Tisch Cancer Institute Clinical Trials Office in New York discusses recent therapeutic advances in multiple myeloma presented at the 2021 ASH annual meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHMM22).
Dr Prithviraj Bose from The University of Texas MD Anderson Cancer Center in Houston, Texas, discusses recent therapeutic advances in myeloproliferative neoplasms presented at the 2021 ASH annual meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHMPN22).
Dr Matthew Lunning from the University of Nebraska Medical Center in Omaha, Nebraska, discusses recent therapeutic advances in Hodgkin and non-Hodgkin lymphomas. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHLymphoma22).
Dr Andrew Brunner from the Massachusetts General Hospital Cancer Center in Boston, Massachusetts, discusses updates from ASH 2021 on the management of acute myeloid leukemia and myelodysplastic syndromes. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHAMLMDS22).
Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses current issues in the research and management of localized estrogen receptor-positive breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayERLocalizedBC22).
Dr Peter Hillmen from the University of Leeds in Leeds, England, discusses recent advances in the management of chronic lymphocytic leukemia. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCLL21/Issue2).
Dr Matthew Davids from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent therapeutic advances in chronic lymphocytic leukemia presented at ASH 2021. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHCLL22).
Dr Saad Zafar Usmani from the Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent therapeutic advances in transplant-ineligible newly diagnosed multiple myeloma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMMElderly22).
Dr Evan Yu from the Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses recent therapeutic advances in metastatic castration-resistant prostate cancer CME information and select publications here (http://www.researchtopractice.com/OncologyTodaymCRPC21/Issue2).
Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora, Colorado, discusses recent therapeutic advances in the management of colorectal cancers. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCRCANAL21/Issue2).
Dr Michael Pishvaian from the Johns Hopkins University School of Medicine in Washington, DC, discusses recent therapeutic advances in pancreatic cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPancreasPARP21).
Dr Alan Bryce from the Mayo Clinic in Phoenix, Arizona, discusses current practice patterns and recent advances in the management of metastatic castration-resistant prostate cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodaymCRPC21/Issue1).
Dr Arvind Dasari from the University of Texas MD Anderson Cancer Center discusses recent advances and future directions for the management of early-stage and advanced colorectal cancers. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCRCAnal21/Issue1).
Dr Bradley Monk from the University of Arizona College of Medicine in Phoenix discusses the management of advanced ovarian cancers. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayOvarian21).
Dr Gregory Riely from the Memorial Sloan Kettering Cancer Center in New York City discusses recent advances and future directions in the management of patients with NSCLC and EGFR exon 20 insertion mutations. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNSCLCEGFR21).
Dr Adil Daud from the UCSF Helen Diller Family Comprehensive Cancer Center discusses recent advances and future directions in the use of immunotherapy for the management of wild-type and BRAF-mutant melanoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMelanomaImmuno21).
Dr Andrew Evens from the Rutgers Cancer Institute in New Jersey discusses the management of newly diagnosed and advanced Hodgkin lymphoma in younger and older patients. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHL21).
Dr Matthew Powell from the Washington University School of Medicine in St Louis, Missouri, discusses therapeutic advances and novel investigational strategies for the management of endometrial cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayEndometrial21).
Dr Arnon Kater from the Amsterdam University Medical Centers in Amsterdam discusses recent advances in the management of chronic lymphocytic leukemia. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCLL21/Issue1).
Dr Michael Savona from Vanderbilt University School of Medicine in Nashville, Tennessee, discusses recent advances and future directions in the management of myelodysplastic syndromes. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMDS21/Issue2).
Dr Jonathon Cohen from the Winship Cancer Institute of Emory University in Atlanta discusses recent advances and future directions in the use of CAR T-cell therapy for the management of non-Hodgkin lymphoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCARTLymphoma21).
Dr Cristina Rodriguez from the Fred Hutchinson Cancer Research Center in Seattle discusses the current management of head and neck cancers. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHeadNeck21).
Dr Ruben Mesa from the Mays Cancer Center in San Antonio, Texas, discusses the pathogenesis and management of myeloproliferative neoplasms. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMPN21).
Dr Michael Mauro from the Memorial Sloan Kettering Cancer Center in New York City, New York, discusses the management of chronic myeloid leukemia. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCML21).
Dr Sumanta Pal from the City of Hope Comprehensive Cancer Center in Duarte, California discusses the management of advanced renal cell carcinoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayRCC21).
Dr Marcia Brose from the Sidney Kimmel Cancer Center in Philadelphia discusses the latest clinical data on targeted therapeutic approaches for the management of advanced thyroid cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayThyroid21/Issue2).
Dr Samuel Klempner from Massachusetts General Hospital in Boston, Massachusetts discusses recent updates on immunotherapy and targeted therapy for gastroesophageal cancers. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayGEJ21/Issue2).
Dr Ian Krop from the Dana-Farber Cancer Institute in Boston discusses recently published and emerging research on the treatment of HER2-low breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHER2LowBC21).
Dr Kathleen Moore from the University of Oklahoma Health Sciences Center in Oklahoma City, Oklahoma, discusses key presentations on gynecologic cancers from the 2021 ASCO Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASCOGyn21).
Dr Lori Wirth from the Massachusetts General Hospital in Boston discusses the latest clinical data and ongoing investigations on targeted therapeutic approaches for the management of RET-altered and NTRK fusion-positive thyroid cancers. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayThyroid21/Issue1).
Dr Joel Neal from Stanford University in Stanford, California, discusses key presentations on lung cancer from the 2021 ASCO Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASCOLung21).
Dr Jesús Berdeja from the Sarah Cannon Research Institute in Nashville, Tennessee, discusses recent advances and future directions in the use of CAR T-cell therapy for the management of multiple myeloma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCARTMM21).
Dr Kristen Ciombor from the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, discusses key presentations on gastrointestinal cancers from the 2021 ASCO Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASCOGI21).
Dr Sara Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses key presentations on breast cancer from the 2021 ASCO Annual meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASCOBreast).
Dr Jaffer Ajani from MD Anderson Cancer Center in Houston, Texas discusses the latest clinical data on immune checkpoint inhibitors and other novel agents in the management of gastroesophageal cancers. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayGEJ21).
Dr Arjun Balar from the NYU Perlmutter Cancer Center in New York discusses key presentations on genitourinary cancers from the 2021 ASCO Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASCOGU21).
Dr Guillermo Garcia-Manero from the MD Anderson Cancer Center discusses clinical data with new and emerging approaches for the management of myelodysplastic syndromes. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMDS21).
Dr Adam Brufsky from the University of Pittsburgh discusses the latest clinical data on HER2-targeted therapy for the management of HER2-positive localized breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHER2LocalizedBC21).
Dr Kevin Kalinsky from Emory University in Atlanta discusses the role of genomic assays in treatment decision-making for patients with hormone receptor-positive, HER2-negative, early-stage breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayEarlyBCGenomicAssays21).
Dr Morie Gertz from the Mayo Clinic in Rochester, Minnesota, discusses the diagnosis and management of amyloid light chain amyloidosis. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayAmyloidosis21).
Mitesh Borad from the Mayo Clinic Comprehensive Cancer Center in Scottsdale, Arizona, discusses the biology of cholangiocarcinoma and clinical data with new and emerging targeted approaches for patients with this disease. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCholangiocarcinoma21).
Dr Roy Herbst from the Yale Cancer Center discusses the clinical data on and optimal use of adjuvant osimertinib for patients with resected non-small cell lung cancer and an EGFR mutation. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayEGFRNSCLC21).
Dr Laurie Sehn from the BC Cancer Center for Lymphoid Cancer in Vancouver, Canada, discusses the latest clinical research findings on non-Hodgkin and Hodgkin lymphomas from the 2020 ASH Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHLymphomaCLL21/Issue2).
Dr Natalie Callander from the University of Wisconsin Carbone Cancer Center discusses key presentations on multiple myeloma, Waldenström macroglobulinemia and amyloidosis from the 2020 ASH Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHMM21).
Dr Roberto Iacovelli from the Fondazione Policlinico Universitario A Gemelli in Rome discusses the spectrum and management of side effects with hormonal therapies in prostate cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayProstateHoromonalTherapy21).
Dr Harry Erba from Duke University in Durham, North Carolina, discusses key presentations on acute myeloid leukemia and myelodysplastic syndromes from the 2020 AS Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHAMLMDS21).
Dr Manmeet Ahluwalia from the Miami Cancer Institute of Baptist Health South Florida discusses recently published and emerging research on the management of CNS metastases in patients with non-small cell lung cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayCNSMetsNSCLC21).
Dr Gilles Salles from Memorial Sloan Kettering Cancer Center in New York discusses recently published and emerging research on the treatment of diffuse large B-cell lymphoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayDLBCL21).
Dr Andrew Wei from the Alfred Hospital and Monash University in Melbourne, Australia, discusses recently published and emerging research on the treatment of acute myeloid leukemia not eligible for intensive induction therapy. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayAMLIntensiveTx21).
Dr Antonio González-Martín from the Clínica Universidad de Navarra in Madrid discusses the latest clinical data on and optimal integration of PARP inhibitors in ovarian cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayFrontLineCLL21).
Professor Solange Peters from Lausanne University Hospital in Switzerland discusses existing and emerging biomarkers of response to cancer immunotherapy. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayImmunotherapies21).
Dr Joseph Mikhael from the Translational Genomics Research Institute in Phoenix, Arizona, discusses agents that have been recently approved for the treatment of multiple myeloma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNewAgentsMM21).
Dr Zofia Piotrowska from the Massachusetts General Hospital in Boston discusses emerging strategies for patients with non-small cell lung cancer and EGFR exon 20 insertion mutations. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayEGFRExon20NSCLC21).
Dr Mark Pegram from the Stanford University School of Medicine discusses the latest clinical data on and optimal use of newly approved therapies for HER2-positive metastatic breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayHER2MetastaticBC21).
Dr Shaji Kumar from the Mayo Clinic in Rochester, Minnesota, and Dr Philip Thompson from the University of Texas MD Anderson Cancer Center discuss the role of minimal residual disease assessment in the management of multiple myeloma and chronic lymphocytic leukemia. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMRD21).
Dr Justin Gainor from the Massachusetts General Hospital in Boston discusses emerging targets in non-small cell lung cancer. CME and select publications here (http://www.researchtopractice.com/OncologyTodayNewTargetsNSCLC21).
Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville discusses the latest clinical data on and optimal management of ER-positive metastatic breast cancer. CME and select publications here (http://www.researchtopractice.com/OncologyTodayERPositivemBC21).
Dr Ann LaCasce from the Dana-Farber Cancer Institute discusses key presentations on chronic lymphocytic leukemia and follicular lymphoma from the 2020 ASH Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHLymphomaCLL21/Issue1).
Dr Kathleen Moore from the University of Oklahoma Health Sciences Center discusses key 2020 presentations on the role of PARP inhibitors and other treatment strategies in the management of advanced ovarian cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodaySGOPARP21).
Dr Steven Coutre from Stanford Medicine in California discusses recently published and emerging research in the front-line treatment of chronic lymphocytic leukemia. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayFrontLineCLL21).
Dr Aaron Gerds from the Cleveland Clinic Taussig Cancer Institute discusses key presentations on myeloproliferative neoplasms from the 2020 ASH Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHAML21).
Dr Matthew Galsky from the Icahn School of Medicine at Mount Sinai in New York discusses recently published and emerging data on newly approved agents for urothelial bladder carcinoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayUBCNovelAgents21)
Dr Corey Langer from the Abramson Cancer Center at the University of Pennsylvania discusses recently published and emerging data on the role of immune checkpoint inhibitors in the treatment of metastatic non-small cell lung cancer without actionable mutations. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayNSCLCWT21)
Dr Shannon Westin from the MD Anderson Cancer Center in Houston, Texas, discusses the role of PARP inhibition in the management of ovarian cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayASCOOvarian20)
Dr Sagar Lonial from the Winship Cancer Institute in Atlanta, Georgia, discuses key presentations on the management of multiple myeloma from the 2020 ASH Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASHMM20)
Dr David Quinn from the University of Southern California in Los Angeles discusses the impact of COVID-19 on the management of cancer and the current challenges he is experiencing as a physician caring for patients at the front line of the pandemic. Additional resources * Lee LYW et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. Lancet 2020;395(10241):1919-26. Abstract (https://pubmed.ncbi.nlm.nih.gov/32473682/) * Malek AE et al. Cancer and COVID-19. Lancet 2020;396(10257):1066-7. Abstract (https://pubmed.ncbi.nlm.nih.gov/33038963/) * Poortmans P et al. Cancer and COVID-19: What do we really know? Lancet 2020;395(10241):1884-5. Abstract (https://pubmed.ncbi.nlm.nih.gov/32479827/) * Xia Y et al. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020;21(4):e180. Abstract (https://pubmed.ncbi.nlm.nih.gov/32142622/) * Yang F et al. Clinical characteristics and outcomes of cancer patients with COVID-19. _J Med Virol _2020;92(10):2067-73. Abstract (https://pubmed.ncbi.nlm.nih.gov/32369209/)
Dr Marjorie Zauderer from Memorial Sloan Kettering Cancer Center in New York discusses recently published and emerging research in the management of mesothelioma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMesothelioma20).
Dr Stephen Liu from Georgetown University Hospital in Washington, DC, discusses recently published and emerging research on the role of immunotherapy combination approaches in the treatment of metastatic non-small cell lung cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayNSCLCWT20).
Dr Ursula Matulonis discusses the role of PARP inhibitors in the treatment of ovarian cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayAACR20).
Dr Hope Rugo discusses the role of PARP inhibitors in the treatment of breast cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayAACR20).
Dr Maha Hussain discusses the role of PARP inhibitors in the treatment of prostate cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayAACR20).
Dr Philip A Philip discusses the role of PARP inhibitors in the treatment of pancreatic cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayAACR20).
Dr Joaquim Bellmunt from the Beth Israel Deaconess Medical Center in Boston discusses the use of immune checkpoint inhibitors in urothelial bladder carcinoma. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayCheckpointInhibitionUBC20).
Dr David O’Malley from the Ohio State University and The James Cancer Center in Columbus discusses the current and future roles of immune checkpoint inhibitors and other novel therapies in the management of gynecologic cancers. CME information and select publications here (https://www.researchtopractice.com/OncologyTodaySGOImmuno20).
Dr Andrew Ko from the University of California, San Francisco discusses recently published and emerging research in the management of pancreatic cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayPancreaticCancer20).
Dr Philip A Philip from the Karmanos Cancer Institute in Detroit, Michigan, discusses recent data sets in gastrointestinal cancers from the ASCO and ESMO 2020 meetings that are most likely to have an impact on clinical practice. Faculty information and select publications here (https://www.researchtopractice.com/OncologyTodayGIJournalClub20).
Dr Sylvia Adams from the Perlmutter Cancer Center in New York discusses recently published and emerging research on the use of immune checkpoint inhibition in breast cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayCheckpointInhibitionBC20).
Dr Eric Klein from the Cleveland Clinic Lerner College of Medicine in Cleveland, Ohio, discusses the role of liquid biopsy for cancer detection, including his experience with the Circulating Cell-Free Genome Atlas study. Faculty information and select publications here (https://www.researchtopractice.com/OncologyTodayLiquidBiopsy20).
Dr Peter Voorhees from the Levine Cancer Institute in Charlotte, North Carolina, discusses novel agents under investigation in multiple myeloma. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayMMNovelAgents20).
Professor Stephen Johnston from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London discusses the role of CDK4/6 inhibitors in adjuvant therapy for ER-positive breast cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayERPositiveEarlyBC20).
Dr Ross Camidge from the University of Colorado in Denver discusses recently published and emerging research in the management of non-small cell lung cancer with ALK and ROS1 rearrangements. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayALKNSCLC20).
Dr Daniel Catenacci from the University of Chicago Medicine and Biological Sciences discusses recently published and emerging research in the management of gastroesophageal cancers. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayGastric20).
Dr Ashish Kamat from the University of Texas MD Anderson Cancer Center in Houston discusses recently published and emerging research on the use of immune checkpoint inhibitors and other novel therapies for patients with urothelial bladder cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayAUABladder20).
For this special edition of Oncology Today, I met with Dr Chung-Han Lee from the Memorial Sloan Kettering Cancer Center in New York to discuss recently published and emerging research on the management of renal cell carcinoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayRCC20).
For this special edition of Oncology Today, I met with Dr Keith Pratz from the University of Pennsylvania in Philadelphia to discuss recently published and emerging research in the use of FLT3 inhibitors for patients with acute myeloid leukemia. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayAMLFLT320).
For this special edition of Oncology Today, I met with Dr Tanya Siddiqi from the City of Hope National Medical Center in Duarte, California, to discuss recently published and emerging research in the use of chimeric antigen receptor T-cell therapy for patients with non-Hodgkin lymphoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCARTNHL20).
For this special edition of Oncology Today, I met with Dr Kim Reiss Binder from the Abramson Cancer Center in Philadelphia to discuss recently published and emerging research on the use of PARP inhibitors in pancreatic cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPARPPanc20).
For this special edition of Oncology Today, I met with Dr Courtney DiNardo from the MD Anderson Cancer Center in Houston, Texas, to discuss recently published and emerging research on the management of acute myeloid leukemia not eligible for intensive induction therapy. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayAMLIntensiveTx20).
For this special edition of Oncology Today, I met with Dr John Pagel from the Swedish Cancer Institute in Seattle to discuss recently published and emerging research in the front-line treatment of chronic lymphocytic leukemia. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayFrontLineCLL20/).
For this special edition of Oncology Today, I met with Dr Craig Moskowitz from the University of Miami Sylvester Comprehensive Cancer Center to discuss recently published and emerging research for the treatment of Hodgkin lymphoma. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayHL20).
For this special edition of Oncology Today, I met with Dr Jeffrey Lancet from the Moffitt Cancer Center in Tampa, Florida, to discuss recently published and emerging research on induction and maintenance strategies for patients with acute myeloid leukemia. CME information and select publications here (http://www.researchtopractice.com/oncologytodayAMLInduction20).
For this special edition of Oncology Today, I met with Dr Susan Domchek from the University of Pennsylvania in Philadelphia to discuss recently published and emerging research on the use of PARP inhibitors in breast cancer. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayBreastPARP20).
For this special edition of Oncology Today, I met with Dr Srdan Verstovsek from the MD Anderson Cancer Center in Houston, Texas, to discuss recently published and emerging research in the management of myeloproliferative neoplasms. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayMPN20).
For this special edition of Oncology Today, I met with Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts to discuss recently published and emerging research in the management of EGFR mutation-positive non-small cell lung cancer. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayEGFRNSCLC20).
For this special edition of Oncology Today, I met with Dr Nikhil Munshi from the Dana-Farber Cancer Institute in Boston to discuss recently published and emerging research on the use of CAR T-cell therapy in multiple myeloma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayCARTMM20).
For this special edition of Oncology Today, I met with Dr Petros Grivas from the Fred Hutchinson Cancer Research Center in Seattle to discuss recently published and emerging research on the use of immunotherapy in the management of urothelial bladder carcinoma. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayUBCImmuno20).
For this special edition of Oncology Today, I met with Dr Nikhil Khushalani from the Moffitt Cancer Center in Tampa, Florida, to discuss recently published and emerging research including the use of the immune checkpoint inhibitors cemiplimab and pembrolizumab in the management of cutaneous squamous cell carcinoma. CME information and select publications here (http://www.researchtopractice.com/OncologyTodaycSCC20).
For this special edition of Oncology Today, I met with Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York to discuss recently published and emerging research in the management of small cell lung cancer (SCLC), including the recent approval of lurbinectedin as second-line treatment for extensive-stage SCLC. CME information and select publications here (https://www.researchtopractice.com/OncologyTodaySCLC20).
For this special edition of Oncology Today, Dr Neil Love discusses recently published and emerging research in follicular lymphoma with Drs Carla Casulo from the University of Rochester Wilmot Cancer Center and John P Leonard from the Weill Medical College of Cornell. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayFL20).
Featuring a roundtable discussion with Drs Axel Grothey and Michael J Overman moderated by Neil Love, MD. CME information and select publications here (http://m.researchtopractice.com/OncologyTodayCRC20).
Dr John Heymach from the MD Anderson Cancer Center discusses the role of anti-angiogenic agents in NSCLC and the status of clinical research for and treatment of lung cancer at MD Anderson during the COVID-19 pandemic. RTP Lung Cancer Summit: https://www.researchtopractice.com/LungCancerSummit20/ Additional Resources Calabro L et al. Challenges in lung cancer therapy during the COVID-19 pandemic. Lancet Respir Med 2020;8(6):542-4. Abstract (https://pubmed.ncbi.nlm.nih.gov/32278368/) Dingemans AC et al. Treatment guidance for patients with lung cancer during the coronavirus 2019 pandemic. J Thorac Oncol 2020;15(7):1119-36. Abstract (https://pubmed.ncbi.nlm.nih.gov/32422364/) Di Noia V et al. Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: The spark that ignites the fire? Lung Cancer 2020;145:208-10. Abstract (https://pubmed.ncbi.nlm.nih.gov/32439211/) Singh AP et al. Management of lung cancer during the COVID-19 pandemic. JCO Oncol Pract 2020:OP2000286. Abstract (https://pubmed.ncbi.nlm.nih.gov/32453656/) Zhao Z et al. Recommendations of individualized medical treatment and common adverse events management for lung cancer patients during the outbreak of COVID-19 epidemic. Thorac Cancer 2020;11(6):1752-7. Abstract (https://pubmed.ncbi.nlm.nih.gov/32291968/)
Is it worthwhile to treat pancreatic cancer? Dr Michael Pishvaian from Johns Hopkins University discusses the use of the PARP inhibitor olaparib and other new developments in the disease. Additional Resources * Golan T et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381:317-27. Full text (https://www.nejm.org/doi/full/10.1056/NEJMoa1903387?url_ver=Z39.88-2003𝔯_id=ori:rid:crossref.org𝔯_dat=cr_pub%20%200pubmed) * Burris HA 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial. J Clin Oncol 1997;15(6):2403-13. Abstract (https://ascopubs.org/doi/abs/10.1200/JCO.1997.15.6.2403) * Conroy T et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25. Correspondence (https://www.nejm.org/doi/full/10.1056/NEJMc1107627?url_ver=Z39.88-2003𝔯_id=ori:rid:crossref.org𝔯_dat=cr_pub%20%200pubmed) * Von Hoff DD et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703. Full text (https://www.nejm.org/doi/10.1056/NEJMoa1304369?url_ver=Z39.88-2003𝔯_id=ori:rid:crossref.org𝔯_dat=cr_pub%20%200www.ncbi.nlm.nih.gov) * Doleh Y et al. Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis. Cancer Med 2020;9:3463-76. Full text (https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.3011) * Mavros MN et al. Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: A population-based analysis. CMAJ 2019;191(21):E574-80. Full text (https://www.cmaj.ca/content/191/21/E574.long) * Lowery MA et al. Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms. JNCI 2018;110(10):1067-74. Full text (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186514/) * O’Reilly EM et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol 2020;38(13):1378-88. Full text (https://ascopubs.org/doi/full/10.1200/JCO.19.02931?url_ver=Z39.88-2003𝔯_id=ori:rid:crossref.org𝔯_dat=cr_pub%20%200pubmed)
Dr Jeff Sharman from the Willamette Valley Cancer Institute and Research Center discusses clinical trials evaluating the use of Bruton tyrosine kinase inhibitors as treatment for patients with SARS-CoV-2. Additional Resources Roschewski M et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Science Immunol 2019;5(48):eabd0110. Abstract (https://immunology.sciencemag.org/content/5/48/eabd0110) AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19 [press release (https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19.html)]. April 14, 2020. Chong EA et al. BTK inhibitors in cancer patients with COVID19: “The winner will be the one who controls that chaos” (Napoleon Bonaparte). Clin Cancer Res 2020;[Published OnlineFirst]. Abstract (https://clincancerres.aacrjournals.org/content/early/2020/04/28/1078-0432.CCR-20-1427) COVID-19 and CLL: Frequently Asked Questions. Hematology.org (https://www.hematology.org/covid-19/covid-19-and-cll). May 6, 2020;Version 1.3. Mehta P et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229);1033-4. Correspondence (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30628-0/fulltext) Koffman B et al. Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. Am J Hematol 2020;[Epub ahead of print]. Correspondence (https://onlinelibrary.wiley.com/doi/10.1002/ajh.25851) Treon ST et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood 2020;135(21):1912–5. Full text (https://ashpublications.org/blood/article/135/21/1912/454437/The-BTK-inhibitor-ibrutinib-may-protect-against)
Oncology nurse practitioner Kelly Goodwin discusses current treatment practices at Massachusetts General Hospital, the challenges encountered treating patients with cancer during COVID-19, and the use of telemedicine in oncology care. Additional Resources Catlin N. Navigating the COVID-19 pandemic as an oncology nurse. Oncology Times 2020;42(8):1,12,17. https://journals.lww.com/oncology-times/Fulltext/2020/04200/ProtectingCancerPatientsDuringthe_Coronavirus.1.aspx (https://journals.lww.com/oncology-times/Fulltext/2020/04200/Protecting_Cancer_Patients_During_the_Coronavirus.1.aspx) Paterson C et al. Oncology nursing during a pandemic: Critical reflections in the context of COVID-19. Semin Oncol Nurs 2020;[Online ahead of print]. Abstract (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177078/) Pelin C et al. Safety at the time of the COVID-19 pandemic: How to keep our oncology patients and healthcare workers safe. J Natl Compr Canc Netw 2020;[Online ahead of print]. Abstract (https://pubmed.ncbi.nlm.nih.gov/32294617)
Dr Benjamin Levy from Johns Hopkins comments on changes to the surgical and targeted treatment of lung cancer during COVID-19 and challenges in the management of immune-related adverse events with immune checkpoint inhibitors. RTP Lung Cancer Summit Presentations (https://www.researchtopractice.com/LungCancerSummit20/) Additional Resources * Banna G et al. How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere. ESMO Open 2020;5(2). Abstract (https://pubmed.ncbi.nlm.nih.gov/32245904/) Kumar S et al. Alternative multidisciplinary management options for locally advanced non-small cell lung cancer during the COVID-19 global pandemic. J Thorac Oncol 2020;[Online ahead of print]. Abstract (https://pubmed.ncbi.nlm.nih.gov/32360578) Thoracic Surgery Outcomes Research Network, Inc. COVID-19 guidance for triage of operations for thoracic malignancies: A consensus statement from Thoracic Surgery Outcomes Research Network. Ann Thorac Surg 2020;[Online ahead of print]. Abstract (https://pubmed.ncbi.nlm.nih.gov/32278755)
Dr Kathleen Moore from the Stephenson Cancer Cetner and co-chair of the SGO 2020 Annual Meeting discusses COVID guidelines and the impact of the pandemic on clinical research and the treatment of ovarian cancer. Akladios C et al. Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN Group for the CNGOF. J Gynecol Obstet Hum Reprod 2020;[Online ahead of print]. Abstract (https://www.ncbi.nlm.nih.gov/pubmed/32247066) Dowdy S, Fader AN. Surgical considerations for gynecologic oncologists during the COVID-19 pandemic. SGO 2020. https://www.sgo.org/clinical-practice/management/covid-19-resources-for-health-care-practitioners/surgical-considerations-for-gynecologic-oncologists-during-the-covid-19-pandemic/ Monk B et al. COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies. Gynecol Oncol 2020;[Online ahead of print]. Abstract (https://pubmed.ncbi.nlm.nih.gov/32370991/) Mueller B. Telemedicine arrives in the UK: '10 years of change in one week.' New York Times, April 4, 2020. https://www.nytimes.com/2020/04/04/world/europe/telemedicine-uk-coronavirus.html Ramirez PT et al. COVID-19 global pandemic: Options for management of gynecologic cancers. Int J Gynecol Cancer 2020;[Online ahead of print]. Abstract (https://pubmed.ncbi.nlm.nih.gov/32221023/) Society of Gynecologic Oncology. Gynecologic oncology considerations during the COVID-19 pandemic. https://www.sgo.org/clinical-practice/management/covid-19-resources-for-health-care-practitioners/gyn-onc-considerations-during-covid-19/ Society of Gynecologic Oncology. SGO 2020 Annual Meeting on Women’s Cancer. https://www.sgo.org/education/annual-meeting-on-womens-cancer/
Dr Julie Gralow, Director of Breast Medical Oncology at the Seattle Cancer Care Alliance, reviews how telemedicine and the screening, diagnosis and treatment of breast cancer have rapidly adapted based on resource limitations and risk factors related to COVID-19. Additional Resources * Soran A et al. Breast cancer diagnosis, and follow-up during COVID-19 pandemic. Eur J Health 2020;16(2):86-8. Abstract (https://pubmed.ncbi.nlm.nih.gov/32285027/) * American College of Surgeons. COVID-19 guidelines for triage of breast cancer patients. https://www.facs.org/covid-19/clinical-guidance/elective-case/breast-cancer * Falandry C et al. Challenges with the management of older patients with cancer during the COVID-19 pandemic. J Geriatri Oncol 2020;[Online ahead of print]. Abstract (https://www.sciencedirect.com/science/article/pii/S1879406820301533)
Dr Leora Horn of Vanderbilt University Medical Center discusses outcomes for patients with lung cancer and COVID-19 as well as the human implications of social distancing. Additional Resources * AACR Virtual Annual Meeting I: April 27-28, 2020. (https://aacr20.onlineeventpro.freeman.com/) * COVID-19 and Cancer. AACR 2020. Session (https://aacr20.onlineeventpro.freeman.com/live-stream/15335630/COVID-19-and-Cancer) * Garassino, MC. TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion): First results of a global collaboration to address the impact of COVID-19 in patients with thoracic malignancies. AACR 2020. Abstract (https://www.abstractsonline.com/pp8/#!/9045/presentation/10927) * Minello A. The pandemic and the female academic. Nature 2020;[Online ahead of print]. Abstract (https://www.ncbi.nlm.nih.gov/pubmed/32303729)
Dr Harold Burstein discusses how breast cancer is currently being managed at the Dana-Farber Cancer Institute with the constraints of social distancing and other COVID-19 considerations. COVID-19-Related Resources in Breast Cancer Dietz JR et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. The COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat 2020;[Online ahead of print]. Abstract (https://link.springer.com/article/10.1007/s10549-020-05644-z) Braunstein LZ et al. Breast radiotherapy under COVID-19 pandemic resource constraints —Approaches to defer or shorten treatment from a Comprehensive Cancer Center in the United States. Adv Radiat Oncol 2020;[Online ahead of print]. Abstract (https://pubmed.ncbi.nlm.nih.gov/32292842) Coles CE et al. International guidelines on radiation therapy for breast cancer during the COVID-19 pandemic. Clin Oncol (R Coll Radiol) 2020;32(5):279-81. https://www.clinicaloncologyonline.net/article/S0936-6555(20)30122-9/pdf (https://www.clinicaloncologyonline.net/article/S0936-6555(20)30122-9/pdf) ESMO. ESMO management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/breast-cancer-in-the-covid-19-era (https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/breast-cancer-in-the-covid-19-era)
In this second episode of our new podcast series, Dr Tom Lynch, who began his position as director of the Fred Hutchinson Cancer Research Center as Seattle became the first epicenter of the COVID-19 pandemic in the United States, comments on the current status of oncology research and data soon to be presented from a Phase III trial evaluating the EGFR TKI osimertinib as adjuvant therapy for patients with non-small cell lung cancer and EGFR tumor mutations. Additional resources: * Lynch TJ et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39. Abstract (https://pubmed.ncbi.nlm.nih.gov/15118073/) * AstraZeneca. [Osimertinib] Phase III ADAURA trial will be unblinded early after overwhelming efficacy in the adjuvant treatment of patients with EGFR-mutated lung cancer [press release (https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/tagrisso-phase-iii-adaura-trial-will-be-unblinded-early-after-overwhelming-efficacy-in-the-adjuvant-treatment-of-patients-with-egfr-mutated-lung-cancer.html)]. April 10, 2020. * National Comprehensive Cancer Network. Short-term recommendations for non-small cell lung cancer management during the COVID-19 pandemic. COVID-19 NCCN guidelines (https://www.nccn.org/covid-19/pdf/COVID_NSCLC.pdf).
On this inaugural episode of our new podcast series, we address the treatment of prostate cancer in the era of COVID-19. Featuring interviews with Drs Neeraj Agarwal, Emmanuel Antonarakis and A Oliver Sartor. Additional Resources * National Comprehensive Cancer Network (NCCN®). Recommendations of the NCCN: Management of prostate cancer during the COVID-19 pandemic. COVID-19 NCCN guidelines (https://2013researchtopractice.cmail19.com/t/y-l-udbbt-trkrhkyuui-b/). * Ueda M et al. Managing cancer care during the COVID-19 pandemic: Agility and collaboration toward a common goal. J Natl Compr Canc Netw 2020;18(4):366-9. Abstract (https://2013researchtopractice.cmail19.com/t/y-l-udbbt-trkrhkyuui-f/)